THE LANCET Global Health

Supplementary appendix

This appendix formed part of the original submission. We post it as supplied by the authors.

Supplement to: Marzolini C, Marra F, Boyle A, Khoo S, Back DJ. Fluvoxamine for the treatment of COVID-19. *Lancet Glob Health* 2022; **10:** e331.

Figure: Drug-drug interaction profile of fluvoxamine when considering 555 comedications listed in the Liverpool COVID drug interaction website.² Green stands for no drug-drug interaction; yellow for drug-drug interactions of weak clinical relevance with no need of additional monitoring or dosage adjustment; amber for drug-drug interactions of potential clinical relevance manageable by dose adjustment or clinical monitoring and red for contra-indicated drug associations that may have deleterious consequences. Besides fluvoxamine, the COVID website provides information on DDIs for 30 additional COVID therapies with a total of 17'000 DDIs recommendations.²

